Realidades y retos del aborto con medicamentos en México. Georgina Sánchez Ramírez

y en la proporción de abortos con nueve semanas o menos de gestación (Popinchalk y Sedgh, 2019).

      Además, ha permitido que la limitación legal pase a tener menos importancia, porque dentro o fuera de la ley, la mayor parte de los abortos ha pasado a ser realizado principalmente con el uso de medicamentos, reduciendo enormemente el riesgo de complicaciones graves asociadas al aborto realizado fuera del marco legal (Vásquez-Quesada y otros, 2020).

      Bibliografía

      Aiken ARA, Starling JE, van der Wal A, van der Vliet S, Broussard K, Johnson DM, Padron E, Gomperts R, Scott JG., 2020, “Demand for Self-Managed Medication Abortion Through an Online Telemedicine Service in the United States” en Am J Public Health, Vol. 10, num. 1, pp. 90–97.

      Andersen KL, Basnett I, Shrestha DR , Shrestha MK, Shan M, Shilu Aryal S, 2016, “Expansion of Safe Abortion Services in Nepal Through Auxiliary Nurse-Midwife Provision of Medical Abortion, 2011-2013” en J Midwifery Womens Health, Vol. 61, núm. 2, pp. 177–184. Banwell SS, Paxman JM, 1992 “The search for meaning: RU 486 and the law of abortion” en Am J Public Health, Vol. 82, núm. 10, pp. 1399–1406.

      Baulieu EE, 1989, “Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor” en Science, Vol. 245, núm. 4924, pp. 1351–1357.

      Berer M, 2020, “Reconceptualizing safe abortion and abortion services in the age of abortion pills: A discussion paper” en Best Pract Res Clin Obstet Gynaecol, Vol. 63, pp. 45-55.

      Briozzo L, Vidiella G, Rodríguez F, Gorgoroso M, Faúndes A, Pons JE, 2006, “A risk reduction strategy to prevent maternal deaths associated with unsafe abortion” en International Journal of Gynecology and Obstetrics, Vol. 95, pp. 221–226.

      Bugalho A, Faúndes A, Jamisse L, Usfá M, Maria E, Bique C, 1996, “Evaluation of the effectiveness of vaginal misoprostol to induce first trimester abortion” en Contraception, Vol. 53, núm. 1, pp. 243-246.

      Cameron S, 2018, “Recent advances in improving the effectiveness and reducing the complications of abortion” en Version 1, F1000Res. 2018; 7: F1000 Faculty Rev- 1881. Published online 2018 Dec 2.

      Diaz Olavarrieta C, Ganatra B, Sorhaindo A, Karver TS, Seuc A, Villalobos A, Sandra G García SG, Pérez M, Manuel Bousieguez M, Sanhueza P, 2015, “Nurse versus physician- provision of early medical abortion in Mexico: a randomized controlled non-inferiority trial” en Bull World Health Organ, Vol. 93, núm. 4, pp. 249-58.

      Drabo S, 2019, “A Pill in the Lifeworld of Women in Burkina Faso: Can Misoprostol Reframe the Meaning of Abortion” en Int J Environ Res Public Health, Vol. 16, núm. 22, p. 4425.

      Endler M, Cleeve A, Sääv I, Gemzell,Danielsson K., 2020, “How task sharing in abortion care became the norm in Sweden: A case study of historic and current determinants and events” en Int J Gynaecol Obstet, Vol. 150, Suppl 1, pp. 34–42.

      Faúndes A, Santos LC, Carvalho M, Gras C, 1996, “Postabortion complications after interruption of pregnancy with misoprostol” en Adv Contracept, Vol. 12, pp. 1–9.

      Faúndes A, Duarte GA, Andalaft-Neto J, Sousa MH, 2004, “The closer you are, the better you understand: the reaction of Brazilian Obstetrician-Gynaecologists to unwanted pregnancy” en Reproductive Health Matters, Vol. 12, 24 Supplement, pp. 47-56.

      Faúndes A, 2018, “Misoprostol, An essential drug in Reproductive Health” en J Pregnancy Reprod, Vol. 2, núm. 4, pp. 1-3.

      Gambir K, Kim C , Necastro KA, Ganatra B, D Ngo T, 2020, “Self-administered versus provider-administered medical abortion” en Cochrane Database Syst Rev núm 3, p. CD013181.

      Garris RE, Kirkwood CF, 1989, “Misoprostol: a prostaglandin E1 analogue” en Clin Pharm, Vol. 8, pp. 627-644.

      Grossman D, Baum SE, Andjelic D, Tatum C Torres G, Fuentes L,Friedman J, Ciccozzi M, 2018, “A harm-reduction model of abortion counselling about misoprostol use in Peru with telephone and in-person follow-up: A cohort study” en PLoS One, Vol. 13, núm. 1, p. e0189195.

      Jerman J, Onda T, Jones RK, 2018, “What are people looking for when they Google “self- abortion”?” en Contraception, Vol. 97, núm. 6, pp. 510–514.

      Kapp N, Eckersberger Er , Lavelanet A, Rodriguez MI, 2019, “Medical abortion in the late first trimester: a systematic review” en Contraception, Vol. 99, núm. 2, pp. 77–86.

      Kerestes CA, Stokedale CK, Bridget-Zimmerman, M, Hardy-Fairbanks, AJ, 2019, “Abortion provider`s experiences and views on self managed medication abortion. An exploratory study” en Contraception, Vol. 100, pp. 160-184.

      Lince-Deroche N, Fetters T, Sinanovic E, Devjee J, Moodley J, Blanchard K, 2017, “The costs and cost effectiveness of providing first-trimester, medical and surgical safe abortion services in KwaZulu-Natal Province, South Africa” en PLoS One, Vol. 12, núm. 4, p. e0174615.

      Løkeland M, Bjørge T, Iversen O-E, Akerkar R, Bjørge L, 2017, “Implementing medical abortion with mifepristone and misoprostol in Norway 1998–2013” en Int J Epidemiol, Vol. 46, núm. 2, pp. 643–651.

      Nivedita K, Shanthini F, 2015, “Is It Safe to Provide Abortion Pills over the Counter? A Study on Outcome Following Self-Medication with Abortion Pills” en J Clin Diagn Res, Vol. 9, núm. 1, pp. QC01–QC04.

      Norman WV, Soon JA, Maughn N, 2013, “Barriers to Rural Induced Abortion Services in Canada: Findings of the British Columbia Abortion Providers Survey (BCAPS)” en PLoS One, Vol. 8, núm. 6, p. e67023.

      Popinchalk A, Sedgh G, 2019, “Trends in the method and gestational age of abortion in high- income countries” en BMJ Sex Reprod Health, Vol. 45, núm. 2, pp. 95–103.

      Powell-Jackson T, Acharya R, Filippi V, Ronsmans C, 2015, “Delivering Medical Abortion at Scale: A Study of the Retail Market for Medical Abortion in Madhya Pradesh, India” en PLoS One, Vol. 10, núm. 3, p. e0120637.

      Raymond E, Chong E, Winikoff, Platais B, Mary M y otros., 2019, “TelAbortion: evaluation of a direct to patient telemedicine abortion service in the United States” en Contraception, Vol. 100, pp. 173–177.

      Rocca CH, Puri, M, Shrestha P, Blum, M, Maharjan D, Grossman D, Regmi K, Darney PD, Harper CC, Vermund SH, 2018, “Effectiveness and safety of early medication abortion provided in pharmacies by auxiliary nurse-midwives: A non-inferiority study in Nepal” en PLoS One, Vol. 13, núm. 1, p. e0191174.

      Rogers C, Sapkota S, PauderR, Dantas JAR, 2019, “Medical abortion in Nepal: a qualitative study on women’s experiences at safe abortion services and pharmacies” en Reprod Health, Vol. 16, p. 105.

      Saleem HT (Monitoring Editor), Narasimhan M, Ganatra B, Kennedy CE, and Cochrane Fertility Regulation Group, 2018, “Medical and surgical abortion for women living with HIV” en Cochrane Database Syst Rev, núm 12, p. CD012834.

      Schiavon R, Troncoso E, 2020, “Inequalities in access to and quality of abortion services in Mexico: Can task-sharing be an opportunity to increase legal and safe abortion care?” en Int J Gynaecol Obstet, Vol. 150, Suppl 1, pp. 25-33.

      Sedgh G, Filippi V, Owolabi OO, Singh SD, y otros, 2016, “Insights from an expert group meeting on the definition and measurement of unsafe abortion” en Int J Gynaecol Obstet, Vol. 134, núm. 1, pp. 104–106.

      Sneeringera RK, Billings DJ, Ganatra B, Bairda T, 2012, “Roles of pharmacists in expanding access to safe and effective medical abortion in developing countries: A review of the literature” en Journal of Public Health Policy, Vol. 33, pp. 218–229.

      Sjöström S, Kopp Kallner H, Simeonova E, Madestam A, Gemzell-Danielsson K, 2016, “Medical Abortion Provided by Nurse-Midwives or Physicians in a High Resource Setting: A Cost-EffectivenessAnalysis” en PLoS ONE, Vol. 11, núm. 6, p. e0158645.

      Sudhinaraset M, Landrian A, Montagu